Mitochondrial ROS contribute to oridonin-induced HepG2 apoptosis through PARP activation

XIAONING LIU, JINGJING KANG, HUI WANG and TAO HUANG

Department of Biochemistry, School of Medicine, Huanghe College of Science and Technology, Zhengzhou, Henan 450063, P.R. China

Received November 9, 2016; Accepted November 10, 2017

DOI: 10.3892/ol.2017.7665

Abstract. Oridonin, the main active constituent of Rabdosia rubescens, is known to exert antitumor activity via the induction of apoptosis in numerous types of human cancer cells. However, the underlying regulatory mechanisms of mitochondrial ROS in oridonin-induced HepG2 apoptosis remain largely unknown, due to limitations of subcellular imaging resolution. Previously, it has been suggested that mitochondria serve a potential role in sensing and signaling cellular redox changes in vital biological processes such as cell death and the abiotic stress response, based on studies involving the mitochondrial-targeted redox-sensitive green fluorescent protein (GFP). To address this, a mitochondrial-targeted Grx1-roGFP2 (mtGrx1-roGFP2) biosensor was implemented to monitor real-time mitochondrial redox changes of HepG2 cells in response to either H$_2$O$_2$/DTT or oridonin/SS31 treatment. It was determined that oridonin caused a perturbation in mitochondrial redox status, which in turn contributed to oridonin-induced apoptosis. Furthermore, a novel mechanism underlying the regulation of mitochondrial redox changes in oridonin-induced HepG2 apoptosis, presumably dependent on PARP cleavage, was proposed. In conclusion, the present study provides evidence in support of mitochondrial redox changes as a potential mediator in the apoptotic activities of oridonin in HepG2 cells, which provides insight into the molecular mechanisms by which mitochondrial redox signaling regulates oridonin-induced apoptosis in cancer therapy, and the development of mitochondria-specific oridonin as a promising novel anticancer therapeutic strategy.

Correspondence to: Dr Xiaoning Liu, Department of Biochemistry, School of Medicine, Huanghe College of Science and Technology, 666 Zijingshan South Road, Zhengzhou, Henan 450063, P.R. China
E-mail: xiaoningliu2016@126.com

Key words: oridonin, apoptosis, mitochondrial reactive oxygen species, mitochondrial redox changes, HepG2, mitochondrial-targeted glutaredoxin1-redox-sensitive green fluorescent protein 2, poly adenosine 5’-diphosphate ribose polymerase

Introduction

Apoptosis, or programmed cell death, is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions (1,2). Evasion of apoptosis serves a vital function in carcinogenesis and numerous novel treatment strategies that may restore the apoptotic signaling pathways towards homeostasis may be feasible for eliminating cancer cells (3,4). Reactive oxygen species (ROS), as signals and modulators for cellular redox changes, are key mediators in the regulation of cell apoptosis (5,6). Modulation of the redox state may potentially trigger apoptotic signaling pathways by cellular FLICE-like inhibitory protein degradation, apoptosis signal-regulating kinase 1 activation, cytochrome c release and interaction of caspase 9/Apoptotic protease-activating factor 1 (7). Previous studies (8-10) concerning the extrinsic and intrinsic pathways of apoptosis have focused on mitochondria, which are the major source of ROS generation and serve a central function in apoptosis regulation (11). It has been suggested that instead of elevating overall cellular ROS, regulation of mitochondrial ROS during apoptosis may be a promising therapeutic strategy in the treatment of various types of cancer (7).

As the most abundant cellular redox buffer, glutathione (GSH) is distributed in at least 9 different subcellular compartments, and protects cells against ROS through the oxidation of GSH to glutathione disulfide (GSSG). The reduced to oxidized glutathione ratio [GSH/GSSG] may be measured to reflect cellular redox changes (12-14). Alternatively, various redox-sensitive fluorescent dyes, such as dihydrodichlorofluorescein (H$_2$DCF) have been frequently used to monitor ROS levels in a number of studies focusing on natural drug-induced apoptosis in cancer (15,16). However, conventional approaches lack either spatiotemporal resolution or specificity resolution (17). This is a critical knowledge gap that has adversely limited the ability to comprehensively probe into the underlying regulatory mechanisms of mitochondrial ROS in natural drug-induced apoptosis in cancer, and has also impeded the development of novel redox-based therapeutic strategies targeting cancer. Previously, genetically-encoded redox-sensitive green fluorescent protein (roGFP) probes have been developed with a suitable range of redox potentials to measure the spatial and temporal intracellular oxidation status by ratiometric analysis, which is compartmental,
real-time, reversible and measures dynamic variation trends compared with other methods for assessing intracellular redox status (13,18-20). Previously, human glutaredoxin1 (Grx1) was fused to the roGFP2 biosensor to facilitate specific real-time equilibration between the sensor protein and the glutathione redox couple, consequently allowing dynamic live imaging of the intracellular glutathione redox potential in different cellular compartments, with unprecedented sensitivity and temporal resolution (14,21). Therefore, the ratiometric Grx1-roGFP2 biosensor targeted to mitochondria may be extremely useful in quantifying mitochondrial redox changes associated with natural drug-induced apoptosis in cancer.

Oridonin, a natural and safe ent-kaurene diterpenoid compound isolated from the plant Rabdosia rubescens, has been demonstrated to induce ROS to mediate apoptosis in multiple types of cancer, including human laryngeal cancer cells (22), human cervical carcinoma HeLa cells (23), hepatocellular carcinoma cells (24,25), human epidermoid carcinoma A431 cells (26,27), human histiocytic lymphoma U937 cells (28), esophageal cancer KYSE-150 cells (29) and rheumatoid arthritis fibroblast-like synoviocytes (30). Furthermore, the combined use of AG1478 and oridonin augments the production of ROS and apoptosis (22,26); Therefore, targeting epidermal growth factor receptor combined with oridonin may be a potentially effective anti-neoplastic therapy. Notably, neither study (31,32) demonstrated that oridonin-induced apoptosis may be conferred by compartmental redox changes in live cells. In the present study, using live-cell imaging, it was demonstrated that the mitochondrial-targeted glutaredoxin1-redox-sensitive green fluorescent protein 2 (mtGrx1-roGFP2) probe expressed in HepG2 cells may be used as a real-time reporter of dynamic redox changes caused by oridonin. The possible regulatory mechanisms of mitochondrial redox signaling contributing to oridonin-induced apoptosis in HepG2 cells were also assessed.

Materials and methods

Reagents and antibodies. Unless stated otherwise, reagents were purchased from Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Oridonin (C29H32O11, MW=364.43; Chemical Abstracts Service registry number, 28957-04-2; lot, H1616026) was purchased from Shanghai Aladdin Bio-Chem Technology Co., Ltd. (Shanghai, China). The oridonin was dissolved in ≥99.7% dimethyl sulphoxide (DMSO; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) with 150 mM as original stock solution. Subsequent to mixing by vortex (1,500 rpm for 10 sec), the solution was then filtered through a 0.22-µm filter, and the solution was used to prepare virus stocks for transduction experiments.  

Stable cell line generation. The human hepatoblastoma HepG2 cell line (37,38), obtained from the American Type Culture Collection (Manassas, VA, USA), was cultured in DMEM containing 10% (v/v) fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) at 37˚C in an atmosphere containing 5% CO₂. HepG2 cells stably expressing the mtGrx1-roGFP2 biosensor were generated by lentiviral transduction (Thermo Fisher Scientific, Inc.) of the plasmids into interim 293T cells (American Type Culture Collection) for 12-24 h at 37˚C and subsequent selection with 2 µg/ml puromycin (39). Colonies were screened for mtGrx1-roGFP2 expression by western blotting and Olympus IX71 reverse fluorescence microscopy (magnification, x100; Olympus Corporation, Tokyo, Japan) at an excitation wavelength of 488 nm with an emission filter of 507 nm. For 12 h prior to treatment, the culture medium was altered to DMEM medium with 2% FBS to decrease the serum effect.

Cell viability assay. The viability of cells was measured with TransDetect™ Cell Counting Kit (CCK, catalog no. FC101-01; Beijing Transgen Biotech Co., Ltd., Beijing, China) according to the manufacturer's protocol (Beijing Transgen
Biotech Co., Ltd.) with minor modifications. Briefly, 100 µl HepG2-mtGrx1-roGFP2 cell suspension was dispensed into 96-well plate (5x10^4 cells/well) and the plate was pre-incubated at 37°C for 24 h, followed by treatment with various concentrations of oridonin (0, 5, 10, 20, 30 or 60 µM) for 8 h. Next, 10 µl (100 µl/ml) of CCK working solution was added to each well of the plate and then incubated at 37°C for 2 h. The absorbance of each well at 450 nm was measured under a multimode plate reader (PerkinElmer, Inc., Waltham, MA, USA). The results representing the average of 5 parallel samples were expressed as the relative percentage of cell growth inhibition.

**Fluorescence microscopy.** MtGrx1-roGFP2-expressing HepG2 cells placed in a Nest-35 confocal dish, where the temperature was maintained at 37°C by a stage top incubator (Tokai Hit Elmer, Inc., Waltham, MA, USA), were treated with H_2O_2 (1 mM) or dithiothreitol (DTT; 2 mM) and/or oridonin (25 µM) or SS31 (100 nM) and imaged using a Nikon A1R confocal laser scanning system (Nikon Corporation, Tokyo, Japan) equipped with a 0.95 numerical aperture (water immersion) objective lens at magnification x40. For excitation of 405-nm (channel 1) and 488-nm (channel 2), fluorescence was measured with a bandpass filter of 500-554 nm. Images were captured and exported to ImageJ software (version 1.50i; National Institutes of Health, Bethesda, MD, USA). Subsequent to setting thresholds to avoid low signal ratio artifacts, false-color ratio images were obtained by dividing the 405-nm image by the 488-nm image on a pixel per pixel basis, as previously described (21).

To confirm the mitochondrial localization of the mtGrx1-roGFP2 probe in stable transfectants, the HepG2 cells expressing mtGrx1-roGFP2 were incubated with a pre-warmed (37°C) roseamine-based MitoTracker probe (100 nM; Thermo Fisher Scientific, Inc.) for 20 min at 37°C in an atmosphere of 5% CO_2 according to the manufacturer's protocol (Thermo Fisher Scientific, Inc.). Cells were visualized using Olympus FV1000 confocal laser scanning microscopy equipped with a magnification, x40 objective (Olympus Corporation) at 579 nm excitation and 599 nm emission wavelengths.

**Analysis of apoptotic cells by flow cytometry.** The percentage of apoptotic cells exposed to oridonin (25 µM) with or without SS31 (100 nM) for 8 h were determined using a commercially available Annexin V-phycocerythrin (PE) apoptosis detection kit according to the manufacturer's protocol (BD Biosciences, Franklin Lakes, NJ, USA) with minor modifications. Briefly, cells were collected and washed twice in ice cold PBS and then resuspended in 100 µl 1X binding buffer at a density of 1x10^5 cells/ml, and then incubated with 5 µl Annexin V-PE and 5 µl 7-aminoactinomycin (7-AAD) in the dark for 15 min at room temperature. Finally, 400 µl of 1X binding buffer was added to each tube. Samples were analyzed using a BD FACS Calibur (BD Biosciences) and BD CellQuest Pro software (version 5.1; BD Biosciences) and evaluated based on the percentage of apoptotic cells that were Annexin V-PE-positive and 7-AAD-positive.

**Observation of morphological changes.** Apoptotic nuclear morphology was assessed using Hoechst 33342 (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) in PBS buffer, as described previously (33). HepG2-mtGrx1-roGFP2 cells were grown in culture at 37°C for 12 h. Following 12 h of incubation at 37°C, the cells were perfused with oridonin (25 µM) in the presence or absence of SS31 (100 nM) at 37°C for 8 h. For morphological observation, cells were incubated with Hoechst 33342 (1 mg/ml) for 25 min at 37°C, washed and then examined using an Olympus FV1000 confocal laser scanning microscopy (Olympus Corporation) equipped with a x40 objective at 350 nm excitation and 461 nm emission wavelengths.

**Western blot analysis.** MtGrx1-roGFP2-expressing HepG2 cells were treated with oridonin (25 µM) with or without SS31 (100 nM) at 37°C. After 8 h, cells were washed twice with ice-cold PBS and solubilized in lysis buffer containing 20 mM Tris (pH 7.5), 135 mM NaCl, 2 mM EDTA, 2 mM DTT, 25 mM β-glycerophosphate, 2 mM sodium pyrophosphate, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate (Sigma-Aldrich; Merck KGaA), 10 mM Na fluoride (NaF; Sigma-Aldrich; Merck KGaA), 10 µg/ml aprotinin, 10 µg/ml leupeptin and 1 mM phenylmethylsulfonyl (PMSF; Sigma-Aldrich; Merck KGaA,) for 30 min on ice. Lysates were centrifuged (15,000 x g) at 4°C for 15 min. Soluble protein were denatured in SDS in a boiling water bath for 5 min, and quantified using Easy II Protein Quantitative Kit (BCA; catalog no. DJ111-01; Beijing Transgen Biotech Co., Ltd.). A total of 10 µl protein was electrophoresed on an 8-12% gel using SDS-PAGE, and transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk for 1 h at room temperature, then incubated overnight with the indicated primary antibodies against PARP (1:1,000 dilution; catalog no. 9532T) at 4°C, prior to incubation with goat anti-rabbit IgG HRP-conjugated secondary antibody (1:10,000 dilution; catalog no. HS101-01) for 2 h at room temperature. Detection was performed using an EasySee Western Blot Kit (catalog no. DW101-01; Beijing Transgen Biotech Co., Ltd.).

**Statistical analysis.** All experimental data obtained from cultured cells are expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS (version 19.0; IBM Corp., Armonk, NY, USA). The data were analyzed using one-way analysis of variance, followed by Bonferroni's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Mitochondrial-targeted Grx1-roGFP2 biosensor functions in HepG2 cells.** Previously, it was demonstrated that ROS induced by oridonin is capable of restoring apoptotic signaling pathways in HepG2 cells (32); however, whether mitochondrial ROS contribute to oridonin-induced apoptosis remains unknown. To monitor mitochondrial ROS in HepG2 cells during oridonin-induced apoptosis, stably transfected HepG2 cells were created with a Grx1-roGFP2 biosensor targeted to mitochondria. As demonstrated in Fig. 1A, the expressed Grx1-roGFP2 co-localized with the mitochondrial-selective probe following confocal laser scanning microscopy, indicating that Grx1-roGFP2 was correctly targeted to mitochondria in the transgenic cells.
To determine whether Grx1-roGFP2 was responsive to mitochondrial redox changes and was able to be ratiometrically measured, HepG2 cells were treated with 1 mM H$_2$O$_2$, followed 180 sec later by exposure to 2 mM DTT. As indicated in Fig. 1B, the addition of H$_2$O$_2$ to the growth medium led to an immediate and marked response, with the 405/488 nm fluorescence ratios of Grx1‑roGFP2 in the mitochondria of HepG2 cells ranging from 1.21 to 3.86, which was maintained for 135 sec until injection of DTT induced its reduction to 1.23. Taken together, these results revealed that Grx1-roGFP2 responded, as reflected in the altered 405/488 nm excitation fluorescence ratio, to mitochondrial redox changes triggered by H$_2$O$_2$ and DTT as authoritative oxidants and reductants, therefore providing a real-time detection system for dynamic and reversible changes to mitochondrial redox status induced by anticancer drugs.

Oridonin induces mitochondrial redox changes in HepG2 cells in a time-dependent manner. The primary aim of the present study was to establish a roGFP-based redox-sensing system to monitor redox changes in mitochondria, and to delineate the molecular mechanisms by which mitochondrial ROS control oridonin-induced apoptosis in HepG2 cells. To address this, Grx1-roGFP2 molecules targeting mitochondria, as aforementioned, were used to measure the perturbation of ROS levels reflected by the 405/488 nm excitation fluorescence ratio, as distinguished from the fluorescent intensity of ROS-specific probe H$_2$DCF, which has traditionally been used as the most applicable tool. However, H$_2$DCF exhibits additional disadvantages, such as being destructive, integrated, irreversible, point-in-time and providing only a static redox status (17,21,40). Representative fluorescence microscope images of mitochondrial Grx1-roGFP2 with corresponding ratiometric analysis are presented in Fig. 2. In the time course experiments, stimulation of HepG2 cells with oridonin at a concentration of 25 µM, responsible for a ~50% inhibitory ratio at 8 h (Fig. 3), resulted in a 3-fold increase in progressive oxidation of the sensor, which plateaued after 160 min. As anticipated, SS31 prevented the oridonin-induced oxidation of mtGrx1-roGFP2, with a decline from 3.65 to 1.22 in the 405/488 nm excitation fluorescence ratio. In general, using mitochondria-localized Grx1-roGFP2, the present study has provided evidence that oridonin causes a disturbance of mitochondrial redox poise in a manner that is reversible and may be captured in real time.

Mitochondrial ROS mediate oridonin-induced apoptosis in HepG2 cells. To additionally explore whether mitochondrial ROS act as mediators in oridonin-induced apoptosis, HepG2 cells were co-incubated with SS31 (100 nM) and oridonin (25 µM) for 8 h at 37˚C. Compared with untreated cells, a marked increase by almost 34.41% in cell apoptosis, as indicated by flow cytometry using an Annexin V-PE Apoptosis Detection kit (Fig. 4A), was observed in response to oridonin treatment. Furthermore, inhibition of apoptosis was induced by SS31, accompanied by a decrease in cell growth inhibition ratio from 38.87 to 5.75%. Consistent with the apoptotic percentage, apoptotic morphology was detected by Hoechst 33342 staining.
As demonstrated in Fig. 4B, nuclear condensation and fragmentation were identified in the HepG2-mtGrx1-roGFP2 cells treated with oridonin, whereas SS31 treatment resulted in the integrity of cell morphology, similar to untreated HepG2 cells. Collectively, these data implicate ROS in the mitochondria as important contributors to oridonin-induced cell apoptosis. Mitochondrial ROS contribute to oridonin-induced PARP activation in HepG2 cells. Hypothetically, oxidant stress-induced redox changes may trigger the activation of PARP, which serves an indispensable role in commonly described initiation pathways and redundant cell death pathways (41-43). To elucidate the molecular mechanism responsible for oridonin-induced apoptosis mediated by mitochondrial redox changes in HepG2 cells, the expression levels of PARP were determined by western blot analysis. As demonstrated in Fig. 5, cleaved PARP protein expression was markedly increased by oridonin at a concentration of 25 µM. However, the activation of PARP cleavage was inhibited by SS31 administration. The results additionally confirm that redox signaling in mitochondria serves as a modulator of oridonin-induced apoptosis through the activation of PARP.

Discussion

Previous studies have indicated that oridonin possesses anti-proliferative and apoptotic activities against a variety of cancer cells (44,45). However, the underlying regulatory mechanisms of mitochondrial ROS in oridonin-induced HepG2 apoptosis remain largely unknown due to limitations of subcellular imaging resolution. Previously, it has been argued that mitochondria are more sensitive to redox perturbation compared with other subcellular compartments, and studies have suggested that mitochondria serve a potential role in sensing and signaling cellular redox challenge in vital biological processes such as cell death and abiotic stress response, based on the mitochondrial-targeted redox-sensitive GFP (41,46). In the present study, the mitochondrial-targeted Grx1-roGFP2 biosensor, which has been demonstrated as a valuable tool in sensing compartmentalized redox status and consequently ROS homeostasis/signaling in human cancer cell lines (47), was applied to monitor temporal changes in the redox status of mitochondria in HepG2 cells in response to either H₂O₂/DTT or oridonin/SS31 (Figs. 1B and 2), indicating that a redox-sensing system in HepG2 cells was successfully established. Based on the regulation of mitochondrial redox changes in oridonin-induced apoptosis (Fig. 4), additional experiments were conducted to elucidate the potential mechanisms of action of mitochondrial redox changes in HepG2 cells, as demonstrated in Fig. 5, which were partially dependent on PARP cleavage. Taken together, the present study provides evidence in support of mitochondrial ROS as a potential marker for oridonin's apoptotic effects.
mediator in the apoptotic activities of oridonin in HepG2 cells, which provides insight on the molecular mechanisms by which mitochondrial redox signaling regulates apoptosis in response to oridonin in cancer therapy. Additional investigations are required for the development of mitochondrial-specific oridonin as a novel promising anticancer therapeutic strategy.

Consistent with previous studies (14,18,20,47), the mtGrx1-roGFP2 redox biosensor exhibited excellent specificity and sensitivity, as exemplified by the response to oridonin in HepG2 cells. Future studies should focus on certain key protein in the signaling pathways associated with apoptosis, including tumor protein (p)53 (35,48) using mtGrx1-roGFP2 to determine whether p53 participates in oridonin-induced apoptosis through the generation of mitochondrial ROS. In principle, such redox-sensing systems may be applied to dissect the regulatory mechanisms of redox signaling, or for drug screening and toxicology (18,21). Redox signaling mechanisms associated with HIV and HIV-Mycobacterium tuberculosis co-infection were examined by performing oxidative stress and antioxidant defense pathway-focused human gene expression arrays (RT2 Profiler™ PCR arrays), using Grx1-roGFP2 (18). Compared with TNF-related apoptosis-inducing ligand (TRAIL) as an acknowledged apoptosis inducer (21), oridonin altered the redox state of the mitochondria to the extent that the mitochondrial sensor demonstrated highly rapid and marked changes in oxidation (Fig. 2), suggesting that the activity of oridonin as a redox-active molecule may be superior to that of TRAIL, and potentially an excellent therapeutic candidate for targeting cancer. However, it should be noted that the activity of the mitochondrial sensor mtGrx1-roGFP2 has not been compared or normalized between HeLa and HepG2 cell lines. Additional studies are required to explore the issue as to which subcellular compartment is more susceptible to redox changes induced by oridonin.

In HepG2 cells, multiple mechanisms, including the inhibition of telomerase, induction of endoplasmic reticulum stress and regulation of p53, MAPK and mitochondrial signaling pathways, have been implicated in the apoptotic activity of oridonin (25,49,50). Whether other mechanisms, such as PARP activation, are associated with the anti-HepG2 activity
of oridonin remains unknown. To the best of our knowledge, for the first time, the present study investigated the involvement of PARP activated by mitochondrial ROS in contributing to oridonin-induced HepG2 apoptosis (Fig. 5), as previously demonstrated in menadione-triggered cell death pathways (41). This provides further insight into the molecular mechanisms of oridonin function in HepG2 cells.

Acknowledgements

The authors would like to thank Professor Dick German Cancer Research Center, Heidelberg, Germany for kindly providing the mtrGrx1-roGFP2 plasmid. The present study was supported by the Natural Science Fundamental Research Program of Henan Provincial Education Department (grant no. 16A180046) and Zhengzhou Science and Technology Development Plan (grant no. 20150350).

References

1. Mohan H: Textbook of pathology. 5th edition. Jaypee Brothers Medical Publishers, New Delhi, pp21-60, 2010.
2. Merkle R: Cellular adaptation, injury and death. In Pathophysiology: Concepts of altered health states. Porth CM and Matfin G (eds). 8th edition. Wolters Kluwer/Lippincott Williams and Wilkins, Philadelphia, PA, pp94-111, 2009.
3. Ghobrial I M, Witzig TE and Adjemian AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 55: 178-194, 2005.
4. Wong RS: Apoptosis in cancer: From pathogenesis to treatment. J Exp Clin Cancer Res 30: 87, 2011.
5. Parri M and Chiarugi P: Redox molecular machines involved in tumor progression. Antioxid Redox Signal 19: 1828-1845, 2013.
6. Tochhawng L, Deng S, Pervaiz S and Yap CT: Redox regulation of cancer cell migration and invasion. Mitochondrion 13: 246-253, 2013.
7. Zhang L, Wang K, Lei Y, Li Q, Nice EC and Huang C: Redox signaling: Potential arbiter of apoptosis and apoptosis in therapeutic response. Free Radiol Biol Med 89: 452-465, 2015.
8. Liao W, Yu Z, Lin Z, Lei Z, Ning Z, Regenstein JM, Yang J and Ren J: Biofunctionalization of Selenium nanoparticle with dietylphoradiusiata polysaccharide and its antiproliferative activity through death receptor and mitochondria-mediated apoptotic pathways. Sci Rep 5: 18629, 2015.
9. Xue M, Ge Y, Yu C, Zheng Z, He X and Zhao J: Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Mol Med Rep 10: 978-982, 2017.
10. Zhang YQ, Xiao CX, Lin BY, Shi Y, Liu YP, Liu JJ, Guleng B and Ren J: Silencing of porrenk enhances caspase-dependent apoptosis via fas- and mitochondria-mediated pathways in hepaticellular carcinoma cells. PLoS One 8: e69981, 2013.
11. Kroemer G: Mitochondrial control of apoptosis: An overview. Biochem Soc Sym 66: 1-15, 1999.
12. Mari M, Morales A, Colell A, Garcia-Ruiz C and Fernandez-Checa JC: Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11: 2685-2700, 2009.
13. Morgan B, Sobotta MC and Dick TP: Measuring GSH and GSSG with roGFP2-based redox probes. Free Radic Biol Med 51: 1943-1951, 2011.
14. Kolossov VL, Hanafin WP, Beaudoin JN, Bica DE, DiLiberto SJ, Kenis PJ and Gaskins HR: Inhibition of glutathione synthesis distinctly alters mitochondrial and cytosolic redox poise. Exp Biol Med (Maywood) 339: 394-403, 2014.
15. Chan CK, Supriadi H, Goh BH and Kadir HA: Elephantopus scaber induces apoptosis through ROS-dependent mitochondrial signaling pathway in HCT116 human colorectal carcinoma cells. J Ethnopharmacol 168: 291-304, 2015.
16. Shen S, Zhang Z, Zhang R and Gong X: Sarsasapogenin induces apoptosis via the reactive oxygen species-mediated mitochondrial pathway and ER stress pathway in HeLa cells. Biochem Biophys Res Commun 15: 519-524, 2013.
17. Ezerina D, Morgan B and Dick TP: Imaging dynamic redox processes with genetically encoded probes. J Mol Cell Cardiol 73: 43-49, 2014.
18. Howar A, Munshi M, Khan SZ, Fatima S, Arya R, Jameel S and Singh A: Measuring glutathione redox potential of HIV-1-infected macrophages. J Biol Chem 290: 1020-1038, 2015.
19. van Lith M, Tiwari S, Pediani J, Milligan G and Bullen NJ: Real-time monitoring of redox changes in the mammalian endoplasmic reticulum. J Cell Sci 124: 2349-2356, 2011.
20. Haniff GT, Aggelker R, Delsecbe D, Cannon M, Capaldi RA, Tsiens RY and Remington SJ: Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. J Biol Chem 279: 13044-13053, 2004.
21. Gutschcher M, Pauleau AL, Marty L, Brach T, Wabnitz GH, Schumann Y, Meyer AJ and Dick TP: Real-time imaging of the intracellular glutathione redox potential. Nat Methods 5: 553-559, 2008.
22. Kang N, Zhang JH, Qu F, Tashiro S, Onodera S and Ikejima T: Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett 294: 147-158, 2010.
23. Zhang YH, Wu YL, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species contribute to oridonin-induced apoptosis and autophagy in human cervical carcinoma HeLa cells. J Immunopharmacol 32: 1266-1275, 2011.
24. Chen G, Wang K, Yang BY, Tang B, Chen JX and Hua ZC: Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol 40: 1447-1454, 2012.
25. Wang H, Ye Y and Yu ZL: Proteomic and functional analyses demonstrate the involvement of oxidative stress in the anticancer activities of oridonin in HepG2 cells. Oncol Rep 31: 2165-2172, 2014.
26. Yu Y, Fan SM, Ye YC, Tashiro S, Onodera S and Ikejima T: The tyrosinase AG14878 augments oridonin-induced A549 cell apoptosis by blockage of JNK MAPK and enhancement of oxidative stress. Free Radi Res 46: 1393-1405, 2012.
27. Yu Y, Fan SM, Song JK, Tashiro S, Onodera S and Ikejima T: Hydroxyl radical (OH) played a pivotal role in oridonin-induced apoptosis and autophagy in human epidermoid carcinoma A431 cells. Biol Pharm Bull 35: 2148-2159, 2012.
28. Zhang L, He H, Xu Q, Yu Y, Zheng N, Liu W, Hayashi T, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species enhance oridonin-induced phagocytosis of apoptotic cells by human histocytic lymphoma U937 cells. Int Immunopharmacol 15: 414-423, 2013.
29. Pijl C, Hai H, Jin H, Yang F, Jiang J, Wu A, Zhu H, Liu J, Su X, Yang P and Cai J: Qualitative and quantitative analysis of ROS-mediated oridonin-induced osseous cancer KYSE-150 cell apoptosis by atomic force microscopy. PLoS One 10: e0140935, 2015.
30. Mita Y, CH, Zhang Q, Zhou H and Orimo A: Human mitochondria cell proliferation and induces apoptosis in rheumatoid arthritis fibroblast-like Synovicyctes. Inflammation 39: 873-880, 2016.
31. Xu ZZ, Fu WB, Jin Z, Guo P, Wang WF and Li JM: Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma. Leuk Lymphoma 57: 888-898, 2016.
32. Huang J, Wu L, Tashiro S, Onodera S and Ikejima T: Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK and mitochondrial signaling pathways. J Pharmacol Sci 107: 370-379, 2000.
33. Bao R, Shu Y, Wu X, Weng H, Ding Q, Cao Y, Li M, Mi J, Wu J, Ding Q, et al: Oridinone induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer 14: 217, 2014.
34. Li C, Chen X, Xiao W, Ma W, Li T, Huang J, Liu X, Liang X, Tang S and Luo Y: Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells. Biochem Biophys Res Commun 404: 349-356, 2011.
35. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW and Szezo HH: Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death and reperfusion injury. J Biol Chem 279: 34682-34690, 2004.
36. Zhao K, Luo G, Giannelli S and Szezo HH: Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyldihydroperoxide in neuronal cell lines. Biochem Pharmacol 70: 1796-1806, 2005.
37. López-Terrada D, Cheung SW, Finegold MJ and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol 40: 1512-1515, 2009.
38. Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, MacLeod RA, Masters JR, Nakamura Y, Reid YA, Reddel RR and Freshney RI: Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer 127: 1-8, 2010.
39. Zufferey R, Nagy D, Mandel RJ, Naldini L and Trono D: Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875, 1997.
40. Rota C, Chignell CF and Mason RP: Evidence for free radical formation during the oxidation of 2′-7′-dichlorofluorescin to the fluorescent dye 2′-7′-dichlorofluorescein by horseradish peroxidase: Possible implications for oxidative stress measurements. Free Radic Biol Med 27: 873-881, 1999.
41. Loor G, Kondapalli J, Schriewer JM, Chandel NS, Vanden Hoek TL and Schumacker PT: Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis. Free Radic Biol Med 49: 1925-1936, 2010.
42. Ye W, Zhong Z, Zhu S, Zheng S, Xiao J, Song S, Yu H, Wu Q, Lin Z and Chen J: Advanced oxidation protein products induce chondrocyte death through a redox-dependent, poly (ADP-ribose) polymerase-1-mediated pathway. Apoptosis 22: 86-97, 2017.
43. Lu P, Kamboj A, Gibson SB and Anderson CM: Poly(ADP-ribose) polymerase-1 causes mitochondrial damage and neuron death mediated by Bnip3. J Neurosci 34: 15975-15987, 2014.
44. Li CY, Wang EQ, Cheng Y and Bao JK: Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int J Biochem Cell Biol 43: 701-704, 2011.
45. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
46. Schwarzlander M, Fricker MD and Sweetlove LJ: Monitoring the in vivo redox state of plant mitochondria: effect of respiratory inhibitors, abiotic stress and assessment of recovery from oxidative challenge. Biochim Biophys Acta 1787: 468-475, 2009.
47. Albrecht SC, Bobe MC, Bausewein D, Aller I, Hell R, Dick TP and Meyer AJ: Redesign of genetically encoded biosensors for monitoring mitochondrial redox status in a broad range of model eukaryotes. J Biomol Screen 19: 379-386, 2014.
48. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA and Finkel T: Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 93: 11848-11852, 1996.
49. Wang H, Ye Y, Chui JH, Zhu GY, Li YW, Fong DW and Yu ZL: Oridonin induces G2/M cell cycle arrest and apoptosis through MAPK and p53 signaling pathways in HepG2 cells. Oncol Rep 24: 647-651, 2010.
50. Wang H, Ye Y, Chui JH, Zhu GY, Fong WF and Yu ZL: Proteomic and functional analyses reveal the potential involvement of endoplasmic reticulum stress and alpha-CP1 in the anticancer activities of oridonin in HepG2 cells. Integr Cancer Ther 10: 160-167, 2011.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.